On the contrary, SGK1 inhibitors (heterocyclic indazole derivatives) are currently being trialed for several pathologies, ranging from diabetes and obesity to kidney disorders [27]. The gene discussed is SGK1; the disease is obesity due to melanocortin 4 receptor deficiency.